Stay updated with breaking news from Nasdaq Srpt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the seventeen research firms that are presently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1-year price objective […]
MBB Public Markets I LLC lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 4.8% in the third quarter, Holdings Channel.com reports. The firm owned 4,000 shares of the biotechnology company’s stock after selling 200 shares during the period. MBB Public Markets I LLC’s holdings in Sarepta Therapeutics were worth […]
Cantor Fitzgerald reissued their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a report released on Wednesday morning, Benzinga reports. Cantor Fitzgerald currently has a $128.00 price objective on the biotechnology company’s stock. Several other equities research analysts have also commented on SRPT. Morgan Stanley cut their price target on shares […]
Sigma Planning Corp lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 2.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 12,405 shares of the biotechnology company’s stock after purchasing an additional 300 shares during the period. Sigma Planning Corp’s holdings in Sarepta Therapeutics […]
M&T Bank Corp increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 13.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,582 shares of the biotechnology company’s stock after acquiring an additional 411 shares during the quarter. […]